- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04279951
Alpha and Omega of Lifestyle Therapy (Alpha&Omega)
Alpha and Omega of Lifestyle Therapy - Resistance Training and Ingestion of n-3 Polyunsaturated Fatty Acids to Improve Health and Muscle Functions in Individuals With Obesity and Healthy Controls
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lifestyle therapy is important for treating lifestyle-related morbidities such as obesity. Such therapy often includes exercise and nutrition, and leads to improved health, functionality and quality of life. Unfortunately, obesity leads to adverse changes in the physiological milieu, including inflammation and altered nutritional status such as reduced omega-3:omega-6 ratios. Indeed, inadequate omega 3 levels are common even among lean individuals. This may negatively affect the outcome of lifestyle therapy with exercise, particularly those involving resistance training, contributing to the large heterogeneity seen in training responses. In accordance with this, many individuals (including both lean and obese subjects) fail to improve muscle biology/functions and health, including failure to increase muscle mass and strength, failure to improve glucose handling and inflammatory status. This makes general lifestyle therapy recommendations ineffective. Here, we investigate effects of double-blinded, randomized placebo-controlled n3-fatty acid supplementation (1000 mg day-1) and 13 weeks of low- and high-load resistance training on muscle growth/function/biology and health in individuals with obesity (BMI>30, n=60) and lean controls (BMI<30, n=60). Each participant will perform two different training protocols, one on each leg. The supplement period will commence 7 weeks prior to the onset of the strength training intervention to ensure adequate omega-3 biology at the onset of training. Analyses include assessment of the separate and combined effects of n3-supplementation and obesity on training responses to resistance training, measured as muscle mass, muscle strength/functionality, muscle biological traits, and systemic health variables such as hormone/inflammation/glucose biology, adipose tissue biology/mass, gut microbiome and health-related quality of life. The project will provide important insight into the feasibility of resistance training and n-3 fatty acid supplementation for treating individuals with obesity, paving the way for personalized lifestyle therapy.
The study has two defined main outcome measures, targeting the combined effects of omega-3 and strength training on i) muscle thickness of the thigh (measured using ultrasound; this main outcome measure targets the effects of the intervention on muscle growth), and ii) glucose tolerance (measured using an oral glucose test; this main outcome measure targets the effects of the intervention on improvements in health).
In our analytical approach, we will use a mixed model-approach to assess the main effects of the intervention, mainly defined as changes from before to after the resistance training intervention. Importantly, for health variables such as glucose tolerance, analyses will be performed by accounting for individual variation at baseline, as any beneficial effect can be expected to be higher/present only in individuals with a pathological/diseased starting point. Notably, for many variables, we will collect data from two additional time points (pre-supplementation and after two weeks of familiarization to training). These data will provide insight into additional perspectives, such as the effects of omega-3 intake-only on glucose tolerance, which will bring additional depth to our conclusions (these analyses are not necessarily specified in the Outcome Measures section). For other data, such as primary cultivation of skeletal muscle and muscle mitochondrial respiration, data will only be collected from a randomized subset of participants. For analyses of the effects of the intervention on obesity-related pathophysiologies and health-related quality of life, data from a group of non-intervention individuals will act as reference values (data sampled alongside the intervention). Finally, we will use regression analyses to explain individual differences in training responses, with particular emphasis on muscle hypertrophy/glucose tolerance and their mechanistic origin of nature.
2021/08: The number of anticipated participants was increased from 120 to 150 due to circumstances relating to the SARS-CoV-2 pandemic
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lillehammer, Norway
- Inland Norway University of Applied Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Untrained (less than 2 sessions of resistance exercise per month and less than 3 hours of endurance exercise per week)
Exclusion Criteria:
- Unstable cardiovascular disease
- Injuries affecting the ability to perform heavy resistance exercise
- Mental illness
- Allergy to local anesthesia
- Smoking
- Use of medicine or drugs containing steroids the last two months prior to inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
No intervention
|
|
Experimental: Omega 3
Intake of 1 gram omega-3 (capsules) per day for 20 weeks + high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training) |
High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
1 gram of omega-3 per day for 20 weeks
Other Names:
|
Placebo Comparator: Placebo
Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks + high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training) |
High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
1 gram of sunflower oleic oil per day for 20 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle thickness, ultrasound
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle thickness of vastus lateralis and vastus intermedius measured using ultrasound
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Glucose tolerance
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Glucose tolerance measured using an oral glucose tolerance test
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lean body mass
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Lean body mass measured using whole-body DXA scan
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Fat mass
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Fat mass measured using whole-body DXA scan
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Visceral fat mass
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Visceral fat mass measured using whole-body DXA scan
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle mass, MRI
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Thigh muscle cross sectional area/volume measured using magnetic resonance imaging (MRI)
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle mass, immunohistochemistry
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Fibre type-specific muscle-fibre cross-sectional area measured using immunohistochemistry
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle mass, combined measure
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle mass of the legs measured as the weighted average of data from ultrasound, MRI, immunohistochemistry and DXA measurements
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle fibre type composition
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle fibre type composition measured using immunohistochemistry
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Myonuclear number
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Fiber type-specific myonuclear number measured using immunohistochemistry
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle satellite cell number
Time Frame: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
Fiber type-specific muscle satellite cell number measured using immunohistochemistry
|
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
Muscle capillarization
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Fiber type-specific muscle capillarization measured using immunohistochemistry
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Fat infiltration (muscle)
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Fat infiltration in thigh muscle measured using magnetic resonance imaging (MRI)
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle quality
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Muscle strength measured per muscle mass of the legs
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Unilateral lower body maximal strength
Time Frame: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
The ability of muscles of the lower body to exert maximal force during dynamic movements
|
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
Unilateral lower body isokinetic muscle strength
Time Frame: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
The ability of the knee extensors to exert maximal force during isokinetic movements
|
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
Unilateral lower body isometric muscle strength
Time Frame: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
The ability of the knee extensors to exert maximal force during isometric actions
|
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
Peak power output during one-legged cycling
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Maximal cycling performance measured as peak power output (Watt) during an incremental one-legged cycling test
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Oxygen consumption during one-legged cycling
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
The ability to consume oxygen during an incremental one-legged cycling test
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Unilateral lower body muscle endurance
Time Frame: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
The ability of muscles of the lower body to perform repeated dynamic contractions at a specified submaximal load (70% of 1RM) to exhaustion
|
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
|
Waist circumference
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Circumference of the waist measured using measuring tape
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Blood pressure at rest
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Blood pressure at rest measured using an automated upper-arm blood pressure cuff
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Hemoglobin glycosylation (HbA1c)
Time Frame: Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Long-term glucose levels measured as hemoglobin glycosylation of the metabolic syndrome such as waist circumference, blood pressure at rest, lipid profile ( hemoglobin glycosylation (HbA1c) and fasting blood glucose
|
Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Fasting blood glucose
Time Frame: Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Fasting blood glucose measured in serum
|
Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
N-3 PUFA (blood)
Time Frame: Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Omega-3 (DHA/EPA) levels in blood
|
Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Inflammatory characteristics of peripheral blood mononuclear cell (PBMC)
Time Frame: Throughout the course of the intervention (weeks 0, 8 and 20)
|
Expression of genes associated with inflammation and lipid metabolism in peripheral blood mononuclear cell measured using quantitative PCR
|
Throughout the course of the intervention (weeks 0, 8 and 20)
|
Lipid concentrations in blood
Time Frame: Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Concentrations of various lipids and lipid metabolites such as triglycerides, LDL, HDL, ceramides, dihydroceramides, glucosylceramides, and lactosylceramides measured in serum using tageted metabolomics
|
Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Nutritent concentrations in blood
Time Frame: Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Concentrations of nutrients (such as amino acids) and ions (such as iron and calcium) measured in serum
|
Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Hormone concentrations in blood
Time Frame: Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Concentrations of hormones such as testosterone, growth hormone, thyroid hormones, cortisol and insulin (as well as c-peptide) measured in serum
|
Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Concentrations of inflammatory factors in blood
Time Frame: Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Levels of inflammatory factors such as IL6, CRP and NFkB in serum
|
Changes throughout the course of the intervention (weeks 0, 8 and 20)
|
Muscle fractional synthesis rate
Time Frame: Week 18 to 20
|
Protein/RNA synthesis rate measured using heavy water (deuterium) and chromatography/spectrometry
|
Week 18 to 20
|
Gene expression in skeletal muscle (intervention)
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
RNA (e.g.
messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as targeted genes and at the level of the transcriptome
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Gene expression in skeletal muscle (familiarization)
Time Frame: Changes from before to after familiarization to resistance exercise (week 8 to 10)
|
RNA (e.g.
messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome
|
Changes from before to after familiarization to resistance exercise (week 8 to 10)
|
Protein abundance in skeletal muscle (intervention)
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Levels of proteins and their modification status (e.g.
phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Protein abundance in skeletal muscle (familiarization)
Time Frame: Changes from before to after the resistance training intervention (week 8 to 10)
|
Levels of proteins and their modification status (e.g.
phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome
|
Changes from before to after the resistance training intervention (week 8 to 10)
|
Mitochondrial functions in muscle
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
The ability of muscle mitochondria (extracted from muscle homogenate) to synthesize ATP in vitro
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Gene expression in subcutaneous fat
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
RNA (e.g.
messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in subcutaneous fat, measured as targeted genes
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Satellite cell proliferation and myotube growth (in vitro)
Time Frame: Changes from before to after N3-supplementation-only (week 0 to 8)
|
The ability of muscle satellite cells (extracted from muscle homogenate) to proliferate (rates of cell division), differentiate into myotubes and subsequently grow (rates of change in myotube size) in primary cultures
|
Changes from before to after N3-supplementation-only (week 0 to 8)
|
Musculoskeletal pain (Nordic Pain Questionnaire)
Time Frame: Changes throughout the course of the training intervention (weeks 0, 8 and 20)
|
Musculoskeletal pain measured using The standardized Nordic Pain Questionnaire
|
Changes throughout the course of the training intervention (weeks 0, 8 and 20)
|
Musculoskeletal pain (VAS)
Time Frame: Changes throughout the course of the training intervention (weeks 0, 8 and 20)
|
Musculoskeletal pain measured using VAS-scale (1-10)
|
Changes throughout the course of the training intervention (weeks 0, 8 and 20)
|
Gastrointestinal symptoms
Time Frame: Changes throughout the course of the training intervention (weeks 0, 8 and 20)
|
Gastrointestinal symptoms such as abdominal discomfort and pain, measured using Rome IV criteria
|
Changes throughout the course of the training intervention (weeks 0, 8 and 20)
|
Gut microbiome (feces, N3-supplementation-only)
Time Frame: Changes from before to after N3-supplementation-only (week 0 to 8)
|
Relative composition of the gut microbiome measured using quantitative polymerase chain reaction
|
Changes from before to after N3-supplementation-only (week 0 to 8)
|
Gut microbiome (feces, training intervention)
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Relative composition of the gut microbiome measured using quantitative polymerase chain reaction
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Fecal short-chained fatty acids (N3-supplementation-only)
Time Frame: Changes from before to after N3-supplementation-only (week 0 to 8)
|
Short chained fatty acids measured in feces
|
Changes from before to after N3-supplementation-only (week 0 to 8)
|
Fecal short-chained fatty acids (training intervention)
Time Frame: Changes from before to after the resistance training intervention (week 8 to 20)
|
Short chained fatty acids measured in feces
|
Changes from before to after the resistance training intervention (week 8 to 20)
|
Arterial stiffness
Time Frame: Throughout the course of the intervention (week 0, 8 and 20)
|
Arterial stiffness measured using pulse-wave velocity
|
Throughout the course of the intervention (week 0, 8 and 20)
|
Health-related quality of life (SF-36)
Time Frame: Changes throughout the course of the intervention (week 0, 8 and 20)
|
Health-related quality of life measured using the SF-36 questionnaire
|
Changes throughout the course of the intervention (week 0, 8 and 20)
|
Health-related quality of life in overweight/obesity
Time Frame: Changes throughout the course of the intervention (week 0, 8 and 20)
|
Health-related quality of life in overweight/obesity individuals measured using The impact of weight on quality of life (IWQOL) questionnaire
|
Changes throughout the course of the intervention (week 0, 8 and 20)
|
Health-related quality of life (PANAS)
Time Frame: Changes throughout the course of the intervention (week 0, 8 and 20)
|
Health-related quality of life measured using the Positive and Negative Affect Schedule (PANAS) questionnaire
|
Changes throughout the course of the intervention (week 0, 8 and 20)
|
Activities of daily living
Time Frame: Changes throughout the course of the intervention (week 0, 8 and 20)
|
Activities of daily living (e.g.
time spent in physical activity, intensities of activities) measured using questionnaire
|
Changes throughout the course of the intervention (week 0, 8 and 20)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Training diary relating to the intervention protocol
Time Frame: Weeks 8 to 20
|
Information about intervention-specific training, including training frequency, volume and load
|
Weeks 8 to 20
|
Dietary registration
Time Frame: Week 0, 8 and 20
|
Dietary registration measured using a food frequency questionnaire, assessing nutritional composition, energy intake and habitual patterns of dietary intake
|
Week 0, 8 and 20
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stian Ellefsen, PhD, Inland Norway University of Applied Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Trainome 2019#015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Resistance exercise
-
Universidade Federal de PernambucoUnknownChikungunya FeverBrazil
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChildhood ObesityUnited States
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension | Healthy
-
Iowa State UniversityCompletedCardiovascular Risk Factor
-
University of AlbertaDexCom, Inc.CompletedType 1 DiabetesCanada
-
VA Office of Research and DevelopmentRecruiting
-
Mekelle UniversityCompleted
-
University of Central FloridaCompletedHealthyUnited States
-
National Taiwan Normal UniversityCompletedExecutive FunctionTaiwan
-
University of AlbertaCompletedType 1 DiabetesCanada